Clinical Characteristics of Study Sample
| Characteristic | Value |
| Number of patients (n) | 56 |
| Mean age (y) | 67.0 (range, 48–78; SD, ±7.9) |
| Prior treatment (n)* | |
| Radical prostatectomy | 10 (13%) |
| Prostate bed radiation | 9 (11%) |
| Metastasis-directed radiation | 4 (5%) |
| Both radical prostatectomy and radiation therapy | 14 (18%) |
| Androgen deprivation therapy or chemotherapy | 28 (35%) |
| Other, unknown | 9 (11%) |
| Currently undergoing androgen deprivation therapy or chemotherapy | 6 (8%) |
| Median PSA level (ng/mL) | 13.7 (range, 0.05–132.5) |
| PET/MR (n) | 40 (71%) |
| PET/CT (n) | 16 (29%) |
| Gleason score at diagnosis (n) | |
| 3 + 3 | 5 (9%) |
| 3 + 4 | 8 (14%) |
| 4 + 3 | 8 (14%) |
| 4 + 4 | 12 (21%) |
| 4 + 5 | 13 (23%) |
| 5 + 4 | 5 (9%) |
| 5 + 5 | 2 (4%) |
| Not applicable | 3 (5%) |
| PSMA PET findings (n) | |
| Bone lesions | |
| 1 lesion | 22 (39%) |
| 2–4 lesions (oligometastatic) | 18 (32%) |
| 5+ lesions | 16 (29%) |
| True-positive bone disease | 43 (77%) |
| False-positive bone disease | 13 (23%) |
| Lymph nodes | |
| None | 26 (46%) |
| Pelvic only | 13 (23%) |
| Nonregional only | 6 (11%) |
| Pelvic and nonregional | 11 (20%) |
| Other sites of metastatic disease | 0 (0%) |
↵* Prior treatment percentage applies only to patients with biochemical recurrence.
PSA = prostate-specific antigen.